GlassScriptPhysician profile
Melinda J Wolf
NPI 1346365582
$8,090.01
in general payments reported to CMS, 2019-2025
67 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $554 · 2021: $1,257 · 2022: $1,490 · 2023: $1,351 · 2024: $1,675 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,201.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $621.85 | 2019-2025 | |
| Janssen Biotech, INC. | $597.67 | 2020-2025 | Darzalex, Rybrevant, Talvey |
| Takeda Pharmaceuticals U.S.A., INC. | $505.76 | 2020-2025 | Alunbrig, Ninlaro, Cuvitru |
| Merck Sharp & Dohme LLC | $496.11 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $414.77 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Incyte Corporation | $386.70 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $342.34 | 2020-2025 | Calquence, Lynparza, Imfinzi |
| Amgen INC. | $257.52 | 2019-2023 | Blincyto, Kyprolis, Tezspire |
| Lilly USA, LLC | $233.04 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
| Regeneron Healthcare Solutions, INC. | $227.02 | 2021-2025 | Libtayo |
| Eisai INC. | $221.07 | 2019-2025 | |
| Seagen INC. | $220.83 | 2020-2023 | Tivdak, Tukysa |
| Genzyme Corporation | $208.58 | 2020-2025 | |
| Pharmaessentia USA Corporation | $207.86 | 2022-2025 | Besremi |
| Taiho Oncology, INC. | $173.18 | 2019-2025 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melinda Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.